non-peptide: what the trials say vs what this community says
Something I keep coming back to: non-peptide: what the trials say vs what this community says.
Holding off on any opinion until phase 3 reports. That is not a satisfying position and it is the honest one.
The analytical point, which this board keeps getting wrong by importing habits from the peptide side.
For a peptide, purity is typically reported as area percent by HPLC with identity by mass spectrometry, and the impurity classes are things like deletion and oxidation products. For a small molecule the relevant impurities are synthetic intermediates, degradants and residual solvents, and identity is established differently.
So the certificate you would want looks different, the questions to ask are different, and a "purity" figure quoted here is not comparable to one quoted on the peptide boards. Anybody posting a result should say what method produced it, which is good practice everywhere and essential here.
What is actually known, and what is being assumed.
Known: it is a small-molecule GLP-1 receptor agonist, dosed daily, with clinical programmes reporting in both obesity and type 2 diabetes. Its tolerability profile broadly resembles the class in the data published so far.
Assumed, frequently and confidently: that milligram comparisons with injectables mean something, that adherence is straightforwardly better because it is a tablet, that peptide purity discussions transfer to it. None of those hold. And nothing containing this compound is approved anywhere, which makes research-use-only material exactly that — not approved for human use.
Not medical advice, obviously, and nothing here is approved for human use. One person with a spreadsheet.
best — the order this archive was captured in
Milligram comparisons across molecule classes are meaningless. Potency is a property of the molecule at its receptor, not of the number on the label.
Assumed the peptide purity conversations transferred and they do not. Different analytical problem entirely.
I would not assume the tolerability profile transfers exactly. Similar class effects, different exposure profile.
do not assume reconstitution intuitions apply, there is nothing to reconstitute
Correction: that is the oral peptide product, which is a different thing entirely. This one is a small molecule.
Agreed that phase 3 is where the comparison becomes fair. Everything before it is inference.
It is a non-peptide small-molecule agonist at the GLP-1 receptor. That is a substantial medicinal chemistry achievement: getting a small molecule to activate a receptor evolved for a peptide ligand.
Cosigning on daily dosing. It changes the exposure profile and it changes adherence, in both directions.
daily dosing, not weekly, so the exposure profile is different
Spent an evening reading about small-molecule agonism at a peptide receptor. Genuinely interesting engineering.
Yes. Oral peptide with an absorption enhancer and oral small molecule are completely different propositions.
ATTAIN and ACHIEVE are the programmes to keep straight
Agreed — non-peptide is the fact that everything else follows from, including the manufacturing and the analytics.
The no-timing-restriction thing is the part I would care about most in practice, and it barely gets mentioned here.
nothing containing this is approved anywhere and research material is not for human use
Is that from the publication or the press release?
Yes — nothing containing this is approved anywhere, and the threads keep forgetting it.
- 1Milligram comparisons across molecule classes are meaningless. Potency is a…7 comments in this branch · started by u/the_poster_in_question_2026